Abstract
PACIFIC trial has manifested a lower incidence of new brain metastasis in the durvalumab group than in the placebo group of patients with unresectable stage III NSCLC. Nevertheless, there are few studies mainly focusing on the effect of durvalumab on brain progression. Patients who receive radiotherapy (RT) may have adverse effects like symptomatic RP (radiation pneumonitis) which could be a life-threatening when combined with drug induced pneumonitis. Because many clinicians hesitate to start durvalumab after concurrent CCRT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
